China Resources Double-Crane Pharmaceutical Co (SHSE:600062) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Resources Double-Crane Pharmaceutical Co EBITDA Margin % Related Terms
China Resources Double-Crane Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co EBITDA Margin % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
SHSE:600062 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a EBITDA Margin % of 21.68% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is near median its historical median of 21.26. Over the past decade, China Resources Double-Crane Pharmaceutical Co's EBITDA Margin % has ranged from 17.39 to 24.84. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #353 out of 956 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is China Resources Double-Crane Pharmaceutical Co's EBITDA Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current EBITDA Margin % of 21.68% is near median its 10-year median of 21.26. Over the past 10 years, this metric has ranged from a low of 17.39 to a high of 24.84. The Drug Manufacturers industry median EBITDA Margin % is 12.52. China Resources Double-Crane Pharmaceutical Co's value of 21.68% is 73.2% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #353 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #353 out of 956 companies for EBITDA Margin %. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median EBITDA Margin % is 12.52. China Resources Double-Crane Pharmaceutical Co's value of 21.68% is 73.2% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own EBITDA Margin % has ranged from 17.39 to 24.84 over the past decade. While the company's 10-year median is 21.26 vs. the industry median of 12.52, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current EBITDA Margin % of 21.68% is 73.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current EBITDA Margin % is 21.68%, which is near median its own 10-year median of 21.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current EBITDA Margin % is 21.68%, which is near median its 10-year median of 21.26 and 73.2% above the Drug Manufacturers industry median of 12.52. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current EBITDA Margin % is 21.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
EBITDA Margin %: 21.68% (near median its 10-year median of 21.26)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 73.2% above the Drug Manufacturers median (#353 of 956)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
